Axsome Therapeutics (AXSM) Competitors

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Axsome Therapeutics (NASDAQ:AXSM) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

Do insiders & institutionals have more ownership in JAZZ or AXSM?

89.1% of Jazz Pharmaceuticals shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 4.3% of Jazz Pharmaceuticals shares are held by company insiders. Comparatively, 22.3% of Axsome Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Is JAZZ or AXSM more profitable?

Jazz Pharmaceuticals has a net margin of -9.91% compared to Axsome Therapeutics' net margin of -49.88%. Jazz Pharmaceuticals' return on equity of 5.02% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	-9.91%	5.02%	1.73%
Axsome Therapeutics	-49.88%	-283.22%	-33.06%

Does the media refer more to JAZZ or AXSM?

In the previous week, Jazz Pharmaceuticals had 10 more articles in the media than Axsome Therapeutics. MarketBeat recorded 20 mentions for Jazz Pharmaceuticals and 10 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 1.40 beat Jazz Pharmaceuticals' score of 0.91 indicating that Axsome Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jazz Pharmaceuticals	11 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility & risk, JAZZ or AXSM?

Jazz Pharmaceuticals has a beta of 0.34, indicating that its share price is 66% less volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500.

Which has preferable earnings & valuation, JAZZ or AXSM?

Jazz Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$4.07B	1.84	$560.12M	-$6.73	-18.29
Axsome Therapeutics	$385.69M	15.33	-$287.22M	-$5.07	-23.37

Do analysts rate JAZZ or AXSM?

Jazz Pharmaceuticals currently has a consensus target price of $181.43, suggesting a potential upside of 47.37%. Axsome Therapeutics has a consensus target price of $178.00, suggesting a potential upside of 50.20%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Axsome Therapeutics is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.87
Axsome Therapeutics	0 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	3.07

Summary

Axsome Therapeutics beats Jazz Pharmaceuticals on 9 of the 17 factors compared between the two stocks.